Cerus Corp
Cerus Corp (CERS) Covered Calls
Cerus Corp trades in the Medical Devices industry with an IV Rank of 50.40%, average versus the past year. CERS's highest covered call setup is the $2.00 strike expiring May 21, 2027, sorted by theoretical annualized return. It's 1.01% out of the money with 189 days to expiration, a 18.69% return until expiration, and a 36.09% theoretical annualized return. Across the setups shown, annualized returns run from 36.09% to 36.09% at strikes between $2.00 and $2.00, with 189 to 189 days to expiration, as of Nov 13, 2026.
Read more
Running CERS covered calls helps you generate income from Cerus Corp shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CERS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If CERS stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CERS covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CERS covered call is worth writing.
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced.
| 2027-05-21 | 189 | 2.00 | 1.01 | 0.35 | 1.20 | 37.00 | 18.69 | 36.09 | -17.68 | +0.70 | 29 | 0.85 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryMedical Devices
- SectorHealthcare
- IV Rank50.40% Moderate
- Market cap (M$)401
- 52 weeks high-42.94%
- 52 weeks low34.69%
- Analyst recommendationStrong Buy
1.00 - Target price$5.12
158.59% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-02
- P/E—
- Future P/E—
- EPS (ttm)-0.04
- EPS growth next 5 years—
As of Nov 13, 2026